Grifols’ Xembify (20% SC Immunoglobulin) Receives FDA’s Approval for the Treatment of Primary Immunodeficiencies

 Grifols’ Xembify (20% SC Immunoglobulin) Receives FDA’s Approval for the Treatment of Primary Immunodeficiencies

Grifols’ Xembify (20% SC Immunoglobulin) Receives FDA’s Approval for the Treatment of Primary Immunodeficiencies

Shots:

  • The approval of Xembify reflects Grifols’ commitment to R+D+i and innovation which enables the company to develop new therapies and enhances its Bioscience Division’s product portfolio
  • Grifol is working with regulatory authorities to seek approval in Canada, Europe and other global markets and plans to launch the Xembify in the US in Q4’19
  • Xembify is a 20% SC Ig solution indicated to treat patients with primary humoral immunodeficiency (PI) aged ≥ 2yrs. Additionally, Grifols’ GamaSTAN & HyperRAB has received FDA’s approval in 2018 for providing protection against hepatitis A and measles & to treat patients exposed to rabies virus

Click here to read full press release/ article | Ref: Grifols | Image: The Corner

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post